Search the record
clear ✕
79 results
Hearing Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development.
house Health Subcommittee · Jul 15, 2026 · Transcript · 19 transcript matches
CARTER, TROY A. "of these actions will be felt for decades and weaken our ability to compete and innovate and lead globally. Dr. Wang, I proudly represent New Orleans, home of world-class research institutions like Tulane University, LSU Health and many others. These institutions rely on federal funding to advocate groundbreaking biomedical research, innovation and develop discoveries to improve lives and health outcomes. How do federal research funding cuts affect the United States' leadership in biomedical research and innovation? the United States' leadership in biomedical research and"
Hearing Protecting American Innovation: The Federal Research Security Enterprise
house Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party · Jul 15, 2026 · Transcript · 8 transcript matches
MOOLENAAR, JOHN R. "Dr. Valdez, does the NIH consider the national security implications of proposed research and research collaborations when conducting pre-award due diligence and proposal reviews? And just a follow-up question, Dr. Valdez. Biomedical research is one of China's strategic priorities, and the CCP has made significant investments to acquire foreign biotechnology, pharmaceuticals, and genomics. What specific steps has NIH taken to protect federally-funded biomedical research from foreign exploitation, and where do you believe additional authorities or resources are needed? Thank you very much...."
Hearing Hearings to examine modernizing the National Institutes of Health, focusing on faster discoveries and more cures.
senate Health, Education, Labor, and Pensions Committee · Feb 3, 2026 · Transcript · 7 transcript matches
MARKEY, EDWARD J. "It is an absolute historic mistake which we are making. How does cutting active research advance NIH's mission to support future biomedical"
CRS Report
Animal Use in Federal Biomedical Research: A Policy Overview
Resources · Dec 28, 2023
Animals commonly are used in federally funded biomedical research for a number of reasons—for example, to better understand the biology of disease or to test the safety and efficacy of medical...
CRS Report
Advanced Research Projects Agency for Health (ARPA-H): Overview and Selected Issues
Reports · May 23, 2023
The Advanced Research Projects Agency for Health (ARPA-H) “advances high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or...
Hearing Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain
house Health Subcommittee · Feb 11, 2026 · Transcript · 5 transcript matches
MILLER-MEEKS, MARIANNETTE "Thank you. Ms. Riley and or Mr. Crowley, should there be the NIH provides research support to academic institutions to advance basic biomedical research. And I've seen this in real time as in academic medicine when I was on faculty. If patented inventions arise from that research, the Bayh-Dole Act allows the private industry to negotiate licensing agreements to further research and develop the invention into new medicine to benefit patients, to take that entity"
Hearing Hearings to examine biomedical research, focusing on keeping America's edge in innovation.
senate Appropriations Committee · Apr 30, 2025 · Request transcript
Testimony MOOLENAAR, JOHN R.
Protecting American Innovation: The Federal Research Security Enterpri...
house Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party · Jul 15, 2026
"Dr. Valdez, does the NIH consider the national security implications of proposed research and research collaborations when conducting pre-award due diligence and proposal reviews? And just a follow-up question, Dr. Valdez. Biomedical research is one of China's strategic priorities, and the CCP has made significant investments to acquire foreign biotechnology, pharmaceuticals, and genomics. What specific steps has NIH taken to protect federally-funded biomedical research from foreign..."
CRS Report
Science and Technology Issues for the 118th Congress
Reports · Oct 15, 2024
The federal government supports scientific and technological advancement directly by funding and performing research and development (R&D) and indirectly by creating and maintaining policies that...
CRS Report
The National Institutes of Health (NIH): Background and Congressional Issues
Reports · Jan 13, 2025
The National Institutes of Health (NIH), under the Department of Health and Human Services (HHS), is the leading federal agency for biomedical and health research. In FY2024, NIH used its over $47...
Hearing Hearings to examine the nomination of Casey Means, of California, to be Medical Director in the Regular Corps of the Public Health Service,...
senate Health, Education, Labor, and Pensions Committee · Feb 25, 2026 · Transcript · 3 transcript matches
CASEY MEANS, MD "participant academic industry research collaboration on early metabolic disease detection. worked held biomedical research positions at the National Institutes of Health, Stanford University, New York University, Oregon Health and Science University, and published this biomedical research in leading medical journals. I was recruited as a faculty course director at Stanford University, where I taught undergraduate and graduate students on nutrition and health. I have served as an associate editor of an international medical Stanford University, New York University, Oregon Health and Science..."
CRS Report
National Institutes of Health (NIH) Funding: FY1996-FY2026
Report · May 18, 2026
This report details the National Institutes of Health (NIH) budget and appropriations process with a focus on FY2025 and FY2026. NIH is the primary federal agency charged with conducting and...
Hearing Fiscal Year 2027 Labor, Health and Human Services, Education, and Related Agencies Bill
house Departments of Labor, Health and Human Services, Education, and Related Agencies Subcommittee · Jun 5, 2026 · Transcript · 2 transcript matches
ADERHOLT, ROBERT B. "And the bill before you today, I think, balances the need for responsible fiscal stewardship while maintaining key investments in biomedical research, America's schools, and the core public health. Following the President's directions, we have taken a close, line-by-line look at every program that's funded in this bill. And in several cases, we had to make some difficult decisions on some so-called things that are nice-to-have"
CRS Report
The Federal Policy for the Protection of Human Research Subjects (Common Rule): Overview and Issues
InFocus · Apr 10, 2026
The Common Rule (45 C.F.R. Part 46, Subpart A, “Basic HHS Policy for Protection of Human Research Subjects”) was first published in 1991 and governs the ethical conduct of human subjects research...
Testimony MOOLENAAR, JOHN R.
Protecting American Innovation: The Federal Research Security Enterpri...
house Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party · Jul 15, 2026
"In this role, he advises DOE leadership on science policy and research security and has been involved in the Department's efforts to strengthen protections for federally funded research in the National Laboratory System. Dr. Patricia Valdez is the Chief Extramural Research Integrity Officer at the National Institutes of Health. In that role, she provides strategic leadership on NIH's research security and integrity policies, including efforts to address foreign interference, research..."
Testimony MILLER-MEEKS, MARIANNETTE
Lowering Health Care Costs for All Americans: An Examination of the Pr...
house Energy and Commerce Committee · Feb 11, 2026
"Thank you. Ms. Riley and or Mr. Crowley, should there be the NIH provides research support to academic institutions to advance basic biomedical research. And I've seen this in real time as in academic medicine when I was on faculty. If patented inventions arise from that research, the Bayh-Dole Act allows the private industry to negotiate licensing agreements to further research and develop the invention into new medicine to benefit patients, to take that entity"
Testimony MARKEY, EDWARD J.
Hearings to examine modernizing the National Institutes of Health, foc...
senate Health, Education, Labor, and Pensions Committee · Feb 3, 2026
"It is an absolute historic mistake which we are making. How does cutting active research advance NIH's mission to support future biomedical"
CRS Report
Human Fetal Tissue Research: Frequently Asked Questions
Reports · Aug 8, 2019
This report provides answers to frequently asked questions concerning the regulation and use of fetal tissue in research, including a description of what constitutes fetal tissue research, uses of...
Testimony DR. PATRICIA VALDEZ
Protecting American Innovation: The Federal Research Security Enterpri...
house Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party · Jul 15, 2026
"Chairman Molinar, Ranking Member Khanna, and distinguished members of the committee, thank you for the opportunity to testify today on behalf of the National Institutes of Health. My name is Patricia Valdez, and I serve as NIH's Chief Extramural Research Integrity Officer. For nearly a decade, I have led NIH's efforts to strengthen research security, promote research integrity, and address foreign interference in federally funded biomedical research. NIH is the world's largest public funder of..."
CRS Report
PREVENT Pandemics Act (P.L. 117-328, Division FF, Title II)
Reports · Aug 15, 2023
The Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act) was enacted on December 29, 2022, as a part of Consolidated Appropriations Act, FY2023...
Testimony DR. PATRICIA VALDEZ
Protecting American Innovation: The Federal Research Security Enterpri...
house Select Committee on the Strategic Competition Between the United States and the Chinese Communist Party · Jul 15, 2026
"NIH closely coordinates with Federal partners to strengthen policies, improve information sharing, harmonize disclosure requirements where appropriate, and provide research security guidance to the research community. Research security is essential to protecting the integrity of the nation's biomedical research enterprise and ensuring that taxpayer-funded research advances U.S. interests. NIH remains committed to strengthening its research security program while supporting the international..."
CRS Report
The Cancer Moonshot: Overview and Issues
Resources · Sep 29, 2023
Cancer was the second-leading cause of death in the United States in 2021. For decades, Congress has maintained a sustained interest in reducing cancer mortality, particularly by funding cancer...
Testimony CARTER, TROY A.
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"of these actions will be felt for decades and weaken our ability to compete and innovate and lead globally. Dr. Wang, I proudly represent New Orleans, home of world-class research institutions like Tulane University, LSU Health and many others. These institutions rely on federal funding to advocate groundbreaking biomedical research, innovation and develop discoveries to improve lives and health outcomes. How do federal research funding cuts affect the United States' leadership in biomedical..."
Testimony SPEAKER_02
Lowering Health Care Costs for All Americans: An Examination of the Pr...
house Energy and Commerce Committee · Feb 11, 2026
"Recent actions threaten the stability of the NIH and FDA and undermine future innovation. This committee can and should shore up federal funding for biomedical research at NIH and stabilize FDA. Every actor in the supply chain plays a role in keeping prices high, and every actor has a role to play in ensuring affordability for both patients and our healthcare"
Testimony CASSIDY, BILL
Hearings to examine modernizing the National Institutes of Health, foc...
senate Health, Education, Labor, and Pensions Committee · Feb 3, 2026
"Labor and pensions will please come to order The National Institutes of Health funds more than 50,000 biomedical research projects a year More than any other institution in the world in an I NIH is careful to say public"
Testimony CASSIDY, BILL
Hearings to examine modernizing the National Institutes of Health, foc...
senate Health, Education, Labor, and Pensions Committee · Feb 3, 2026
"Well now that if my math's right, it's been 10 10 and now it's 10 again. It is now 2026 once more we are on schedule to strengthen NIH and American leadership in biomedical research Now putting down partisan jerseys working together to improve families"
Testimony HON. JAYANTA BHATTACHARYA, M.D., PH.D.
Hearings to examine modernizing the National Institutes of Health, foc...
senate Health, Education, Labor, and Pensions Committee · Feb 3, 2026
"say up front, though, that the United States is still the single best place in the world to have a career in biomedical research. I think 85% of all public funding for biomedical research, including foundation money, worldwide public funding for biomedical research, including foundation money,"
Testimony HON. JAYANTA BHATTACHARYA, M.D., PH.D.
Hearings to examine modernizing the National Institutes of Health, foc...
senate Health, Education, Labor, and Pensions Committee · Feb 3, 2026
"We spent the entire allocation that Congress gave in 2025. and the world to do biomedical research, especially for young researchers. Thank you, Mr."
Testimony DEGETTE, DIANA
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"Thank you so much, Mr. Chairman. I am really excited about this hearing today because I've really worked a lot on biomedical research issues over my career, and I have to I think that I've never seen a more precarious time for the U.S. leadership around the world in biomedical research. The FDA plays a critical role in regulating clinical trials, I think that I've never seen a more precarious time for the U.S. leadership around the world in biomedical research. The FDA plays a critical role in..."
Testimony DEGETTE, DIANA
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"everybody was saying there's a cure around the corner, no problem, and all these years have gone by. But all of us have shared a lifetime commitment to advancing treatments, therapies, and ultimately cures. And it has been extraordinary to see what has transpired. And this is why I'm so happy Dr. Kowalski's here, and it'll blow your mind when he talks to you about some of this research, but also the others here today, what's happening in biomedical research in this country. And I know that..."
Testimony DEGETTE, DIANA
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"rowing together in the same direction, and I think we know what we need to do. The federal government and FDA in particular really do have an immense impact on biomedical research and with grants and other collaborations, but as all of you know, our resources are not unlimited, so we have to fund high quality basic research and impactful public health projects. Dr. Kowalski, I wonder if you can talk to us about the importance of merit-based peer review"
Testimony PALLONE, FRANK
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"In May, the Trump administration took another harmful step to decimate our public research when OMB overhauled the federal grant rules and gave political leadership final authority over discretionary award decisions. This politicizes science and threatens the independence of scientific research in the United States. On Monday, a group of 57 organizations representing patients, caregivers, and families that rely on drug discovery wrote to congressional leadership warning of, I quote, profound..."
Testimony KELLY, ROBIN L.
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"Patients and families across the country count on our scientific infrastructure to develop lifesaving treatments, which is why it's so important to invest in biomedical research while simultaneously supporting access for those who need it most. In 2022, along with my colleague, Representative"
Testimony LANGWORTHY, NICHOLAS A.
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"Thank you, Mr. Chairman. The United States has long been the world's leader in biomedical innovation and American researchers, universities, and life science companies have developed groundbreaking treatments that have improved, in many cases, saved millions of lives of people not just here in the United States, but around the world. As other countries work aggressively to attract biomedical research and early-stage clinical development, we should be looking for opportunities to modernize..."
Testimony TRAHAN, LORI
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"Ten scientists were furloughed. It's possible that the products they were working on will never see a pivotal clinical trial. And as if that wasn't bad enough, it gets worse. OMB just proposed a rule that takes that exact mechanism, termination for convenience, and makes it the law for every federal grant in our country. That same rule replaces the scientific review process with political appointees, upending years of stability that has made the United States the global gold standard when it..."
Testimony TRAHAN, LORI
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"what it means for early-stage researchers to have this codified in federal regulation and how will it change what recourse a company has when its grant is simply terminated? I agree. You know, that's why I led more than 100 members warning OMB about the potentially disastrous consequence on this rule, specifically on our biomedical research infrastructure. I'd like to enter into the record the response we received from Director"
Testimony DR. GLENN GRAHAM
Hearings to examine advancing the mission, focusing on evaluating the ...
senate Veterans' Affairs Committee · Jul 22, 2026
"While it may seem modest on the surface, the impacts are likely greater than the magnitude suggests. The NIH projects an approximately 2.7% rate of biomedical research inflation, so the loss of research purchasing power is closer to 5% than 2%. At a time when other traditional funders of research, such as NIH, are undergoing major changes, the VA research budget takes on even greater importance. Even including VERA offset support, research expenditures represent only about 1% of the total VHA..."
Testimony CASSIDY, BILL
Business meeting to consider S.2355, to amend the Public Health Servic...
senate Health, Education, Labor, and Pensions Committee · Jul 22, 2026
"I have long called on the NIH to increase focus on nutrition and obesity, including in my 2024 NIH Modernization White Paper. In Louisiana, the Pennington Biomedical Research Center is doing cutting-edge work to improve our understanding of how nutrition affects health. The NIH provisions of the bill strengthens research on food and dietary patterns and the relationship between diet and chronic"
Testimony MURRAY, PATTY
Business meeting to consider the nominations of Brett Matsumoto, of Ma...
senate Health, Education, Labor, and Pensions Committee · Jul 15, 2026
"Now, I am a huge proponent for vaccine research, which is why I, too, as Senator Ickenlooper just asked you about, Mr. Kaufman, about the cancelling the $500 million in mRNA vaccine research through BARDA, which is they prepare our country for any kind of future issues like we all know we've had now. And last August, they canceled that. And we know that the mRNA technology has grown tremendously and provides new opportunities for biomedical research. You said you agreed with the Secretary's..."
Testimony MURRAY, PATTY
Hearings to examine the nominations of Sean Kaufman, of Georgia, to be...
senate Health, Education, Labor, and Pensions Committee · Jul 15, 2026
"And last August, they canceled that. And we know that the mRNA technology has grown tremendously and provides new opportunities for biomedical research. You said you agreed with the Secretary's decision to eliminate that. I am where Senator Ickenlooper"
Testimony SPEAKER_07
“Training Activists, Not Physicians: The Impact of DEI on Medical Scho...
house Education and Workforce Committee · Jul 14, 2026
"Yes. As Dr. Harwood mentioned, the importance of federal funding for biomedical research cannot be overstated. And in particular, our ability to have the workforce of the physician scientist workforce renewed and have people continue to actually make the discoveries that is our hope that we can begin to use the new tools available to us to begin to predict risk and begin"
Testimony DEGETTE, DIANA
Markup of Fifteen Bills
house Energy and Commerce Committee · Jun 25, 2026
"Advocates tell me that the analysis recommended placing xylosine in Schedule 5, but we're still waiting to see that. And so what my amendment would do is it would place xylosine in Schedule 5 rather than Schedule 3, maintaining DEA's ability to track and prosecute misuse of xylosine, while also protecting biomedical research and substance abuse treatment efforts. I suspect that it will also save federal money that would otherwise be wasted over criminalizing xylosine, but we wouldn't know..."
Testimony DELAURO, ROSA L.
Fiscal Year 2027 Defense Bill
house Appropriations Committee · Jun 24, 2026
"allowed to take effect. I will be happy to provide, and I will provide you with copies copies of what the New England Journal of Medicine has said here. They go on that given political appointees' ultimate authority to determine federal grant funding as proposed by the OMB would politicize and weaken biomedical research. And it's staggering what the effect of this rule would"
Testimony ROUNDS, MIKE
Hearings to examine AI and the American dream, focusing on promoting i...
senate Banking, Housing, and Urban Affairs Committee · Jun 11, 2026
"takes the lead on the development of artificial intelligence in this once-in-a-generation opportunity to advance GDP in our country? Can you imagine a world in which if you use artificial intelligence correctly, you can actually improve the quality of life for Americans? We don't talk about it much, but what happens as we integrate biomedical research and the development of artificial intelligence, being able to make decisions at a very, very rapid pace? Mr. Flynn, does that make a difference..."
Testimony ADERHOLT, ROBERT B.
Fiscal Year 2027 Labor, Health and Human Services, Education, and Rela...
house Appropriations Committee · Jun 5, 2026
"And the bill before you today, I think, balances the need for responsible fiscal stewardship while maintaining key investments in biomedical research, America's schools, and the core public health. Following the President's directions, we have taken a close, line-by-line look at every program that's funded in this bill. And in several cases, we had to make some difficult decisions on some so-called things that are nice-to-have"
Testimony COLE, TOM
Fiscal Year 2027 Labor, Health and Human Services, Education, and Rela...
house Appropriations Committee · Jun 5, 2026
"core, the FY27 bill is about investing in the well-being and potential of America. Think about the people whose futures are shaped by the investments in this measure, the researcher searching for a breakthrough treatment, the student preparing for a career, the parent relying on a rural hospital, the worker learning a new trade. Their success strengthens our communities and ultimately our country. This legislation invests in the biomedical research that keeps America at the forefront of..."
Testimony DEGETTE, DIANA
Full Committee Markup of 16 Bills
house Energy and Commerce Committee · May 21, 2026
"Our constituents are sounding the alarm on patient access, medical innovation, and public health and demanding that we pursue bold legislation to fix these crises, not just reauthorization of existing programs. I urge my colleagues to support these bills, advance them to the floor expeditiously, and to use this momentum to further defend our public health infrastructure, biomedical research agencies, and the American patients that they will ultimately serve. And I yield"
Testimony CASEY MEANS, MD
Hearings to examine the nomination of Casey Means, of California, to b...
senate Health, Education, Labor, and Pensions Committee · Feb 25, 2026
"participant academic industry research collaboration on early metabolic disease detection. worked held biomedical research positions at the National Institutes of Health, Stanford University, New York University, Oregon Health and Science University, and published this biomedical research in leading medical journals. I was recruited as a faculty course director at Stanford University, where I taught undergraduate and graduate students on nutrition and health. I have served as an associate..."
Testimony CASEY MEANS, MD
Hearings to examine the nomination of Casey Means, of California, to b...
senate Health, Education, Labor, and Pensions Committee · Feb 25, 2026
"Absolutely. I 100% agree with you. And also, as a biomedical researcher and physician, I am not going to sit here and say that we not a political We should study the different factors that may"
CRS Report
Congressionally Directed Medical Research Programs Funding for FY2026
InFocus · Mar 4, 2026
Members of Congress are frequently lobbied to add funding to annual defense appropriation legislation for certain medical research programs on a wide variety of diseases and topics. In addressing...
Hearing Hearings to examine advancing the mission, focusing on evaluating the future of VA research.
senate Veterans' Affairs Committee · Jul 22, 2026 · Transcript
DR. GLENN GRAHAM "While it may seem modest on the surface, the impacts are likely greater than the magnitude suggests. The NIH projects an approximately 2.7% rate of biomedical research inflation, so the loss of research purchasing power is closer to 5% than 2%. At a time when other traditional funders of research, such as NIH, are undergoing major changes, the VA research budget takes on even greater importance. Even including VERA offset support, research expenditures represent only about 1% of the total VHA"
Hearing Business meeting to consider S.2355, to amend the Public Health Service Act to provide for hospital and insurer price transparency, S.4189, to...
senate Health, Education, Labor, and Pensions Committee · Jul 22, 2026 · Transcript
CASSIDY, BILL "I have long called on the NIH to increase focus on nutrition and obesity, including in my 2024 NIH Modernization White Paper. In Louisiana, the Pennington Biomedical Research Center is doing cutting-edge work to improve our understanding of how nutrition affects health. The NIH provisions of the bill strengthens research on food and dietary patterns and the relationship between diet and chronic"
Hearing Business meeting to consider the nominations of Brett Matsumoto, of Maryland, to be Commissioner of Labor Statistics, Department of Labor, James...
senate Health, Education, Labor, and Pensions Committee · Jul 15, 2026 · Transcript
MURRAY, PATTY "Now, I am a huge proponent for vaccine research, which is why I, too, as Senator Ickenlooper just asked you about, Mr. Kaufman, about the cancelling the $500 million in mRNA vaccine research through BARDA, which is they prepare our country for any kind of future issues like we all know we've had now. And last August, they canceled that. And we know that the mRNA technology has grown tremendously and provides new opportunities for biomedical research. You said you agreed with the Secretary's decision to eliminate"
Hearing Hearings to examine the nominations of Sean Kaufman, of Georgia, to be Assistant Secretary for Preparedness and Response, and Erica Schwartz, of...
senate Health, Education, Labor, and Pensions Committee · Jul 15, 2026 · Transcript
MURRAY, PATTY "And last August, they canceled that. And we know that the mRNA technology has grown tremendously and provides new opportunities for biomedical research. You said you agreed with the Secretary's decision to eliminate that. I am where Senator Ickenlooper"
Hearing “Training Activists, Not Physicians: The Impact of DEI on Medical Schools”
house Education and Workforce Committee · Jul 14, 2026 · Transcript
SPEAKER_07 "Yes. As Dr. Harwood mentioned, the importance of federal funding for biomedical research cannot be overstated. And in particular, our ability to have the workforce of the physician scientist workforce renewed and have people continue to actually make the discoveries that is our hope that we can begin to use the new tools available to us to begin to predict risk and begin"
Hearing Markup of Fifteen Bills
house Health Subcommittee · Jun 25, 2026 · Transcript
DEGETTE, DIANA "Advocates tell me that the analysis recommended placing xylosine in Schedule 5, but we're still waiting to see that. And so what my amendment would do is it would place xylosine in Schedule 5 rather than Schedule 3, maintaining DEA's ability to track and prosecute misuse of xylosine, while also protecting biomedical research and substance abuse treatment efforts. I suspect that it will also save federal money that would otherwise be wasted over criminalizing xylosine, but we wouldn't know because we haven't yet seen a CBL score for this"
Hearing Fiscal Year 2027 Defense Bill
house Appropriations Committee · Jun 24, 2026 · Transcript
DELAURO, ROSA L. "allowed to take effect. I will be happy to provide, and I will provide you with copies copies of what the New England Journal of Medicine has said here. They go on that given political appointees' ultimate authority to determine federal grant funding as proposed by the OMB would politicize and weaken biomedical research. And it's staggering what the effect of this rule would"
Hearing Hearings to examine AI and the American dream, focusing on promoting innovation, affordability and American dominance.
senate Banking, Housing, and Urban Affairs Committee · Jun 11, 2026 · Transcript
ROUNDS, MIKE "takes the lead on the development of artificial intelligence in this once-in-a-generation opportunity to advance GDP in our country? Can you imagine a world in which if you use artificial intelligence correctly, you can actually improve the quality of life for Americans? We don't talk about it much, but what happens as we integrate biomedical research and the development of artificial intelligence, being able to make decisions at a very, very rapid pace? Mr. Flynn, does that make a difference for the quality of life for the American"
Hearing Full Committee Markup of 16 Bills
house Energy and Commerce Committee · May 21, 2026 · Transcript
DEGETTE, DIANA "Our constituents are sounding the alarm on patient access, medical innovation, and public health and demanding that we pursue bold legislation to fix these crises, not just reauthorization of existing programs. I urge my colleagues to support these bills, advance them to the floor expeditiously, and to use this momentum to further defend our public health infrastructure, biomedical research agencies, and the American patients that they will ultimately serve. And I yield"
Hearing Hearings to examine made in America, focusing on restoring trust in our medicines.
senate Aging (Special) Committee · Nov 19, 2025 · Transcript
GILLIBRAND, KIRSTEN E. "Dr. Edwards, you mentioned your groundbreaking partnership with the Administration for Strategic Preparedness and Response, known as ASPR. In your testimony, Dr. Cockle, or Mr. Cockle, you mentioned in your testimony that your facility in Petersburg, Virginia is funded with U.S. government support with ASPR through the Center of Biomedical Advanced Research and Development Authority, known as BARDA. So can you both, Dr. Edwards and Mr. Cockle, speak about your experiences, what's working, what's not"
Hearing “Building an AI-Ready America: How AI Is Creating Opportunities Across America's Workforce”
house Education and Workforce Committee · Jul 24, 2026 · Transcript
DR. JEFFERY TALBERT "Chairman Allen, Ranking Member McBath, and members of the committee, thank you for the opportunity to testify today on how artificial intelligence is creating opportunities across America's health care workforce. My name is Jeffrey Talbot, Professor and Chair of the Department of Artificial Intelligence and Health at Augusta University's Medical College of Georgia, and a Georgia Research Alliance eminent scholar with over 30 years of experience in biomedical informatics. The Medical College of Georgia is one of the largest medical schools in the"
Hearing Hearings to examine truth in drug labeling.
senate Aging (Special) Committee · Jan 29, 2026 · Transcript
GILLIBRAND, KIRSTEN E. "I want to introduce Stephen Colville. Mr. Colville is an Assistant Research Director at the Duke-Margolis Institute for Health Policy, where he leads the Duke-Margolis Revamp Drug Supply Chain Consortium and policy work on other supply chain and biomedical innovation topics. Previously, Mr. Colville served in the White House Domestic Policy Council as Senior"
CRS Report
Abortion Funding Restrictions in Foreign Assistance Legislation
Resources · Apr 12, 2024
For over five decades, Congress has enacted abortion-related funding restrictions in U.S. foreign assistance legislation. Many of the restrictions were adopted against the backdrop of the Supreme...
CRS Report
Science and Technology Issues for the 119th Congress
Report · Apr 2, 2026
Science and technology (S&T) underlie a wide range of issues confronting the nation. The advancement of S&T can drive economic growth, help address national priorities, and improve health and quality...
CRS Report
NIH Indirect Costs Policy for Research Grants: Recent Developments
Legal Sidebar · Apr 17, 2026
On February 7, 2025, the National Institutes of Health (NIH), an agency of the Department of Health and Human Services (HHS), published supplemental policy guidance that instituted a 15% indirect...
CRS Report
U.S. Public Health Service: COVID-19 Supplemental Appropriations in the 116th Congress
Reports · Mar 11, 2021
Within the Department of Health and Human Services (HHS), eight agencies and two offices are designated components of the U.S. Public Health Service (PHS). Some of these agencies and offices—for...
CRS Report
Advanced Gene Editing: CRISPR-Cas9
Reports · Dec 7, 2018
Scientists have long sought the ability to control and modify DNA—the code of life. A gene editing technology known as CRISPR-Cas9 offers the potential for substantial improvement over other gene...
Testimony HICKENLOOPER, JOHN W.
Hearings to examine modernizing the National Institutes of Health, foc...
senate Health, Education, Labor, and Pensions Committee · Feb 3, 2026
"researchers have conducted numerous studies on the platform, mRNA, and that research has been used as the basis for vaccine development projects at the Biomedical Advanced Research and Development Authority, BARDA, to great success and goes back through – I"
Testimony GILLIBRAND, KIRSTEN E.
Hearings to examine made in America, focusing on restoring trust in ou...
senate Aging (Special) Committee · Nov 19, 2025
"Dr. Edwards, you mentioned your groundbreaking partnership with the Administration for Strategic Preparedness and Response, known as ASPR. In your testimony, Dr. Cockle, or Mr. Cockle, you mentioned in your testimony that your facility in Petersburg, Virginia is funded with U.S. government support with ASPR through the Center of Biomedical Advanced Research and Development Authority, known as BARDA. So can you both, Dr. Edwards and Mr. Cockle, speak about your experiences, what's working,..."
Testimony SPEAKER_06
Lowering Health Care Costs for All Americans: An Examination of the Pr...
house Energy and Commerce Committee · Feb 11, 2026
"cause autism. As a mom of four, I can empathize with parents who are searching for what may be causing their child's autism, but I can affirmatively say it is not due to vaccines. Thank you for the question, and I could not agree more the importance of having the U.S. maintain its lead in biomedical innovation and research. I think there are a number of steps that we should be taking to ensure that we remain that"
Testimony DR. THOMAS HWANG
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"For example, these studies may use a suboptimal control group that does not reflect standard of care in the U.S. The entire biomedical enterprise suffers when clinical research moves to sites with inferior standards for data integrity, safety, and ethical protection of participants. As this subcommittee looks forward to an upcoming reauthorization of user fee"
Testimony CAMMACK, KAT
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"Yes. All right. So clinical development is increasingly global, as been highlighted here today, but the United States can remain a leader in biomedical innovation by strengthening our domestic research ecosystem domestic research ecosystem while continuing to build on those trusted partnerships with countries that share our regulatory standards and commitment to high-quality"
Testimony TRAHAN, LORI
Lowering Health Care Costs for All Americans: An Examination of the Pr...
house Energy and Commerce Committee · Feb 11, 2026
"Today, China-based companies account for a significant share of global trial starts and are running phase one trials faster and at a lower cost than in the U.S. Ms. Riley, in light of this global competition, what concrete steps should Congress take to strengthen America's clinical trial and biomedical innovation ecosystem, including ensuring stable federal research investments so that we remain the world leader in developing new cures without compromising safety or patient protections? Thank..."
Testimony BARRAGÁN, NANETTE DIAZ
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"does it help if we continue to have hostility to international students from abroad? So, it doesn't help that that's happening. And does it help us be leaders in biomedical innovation if the United States is attacking research institutions here? and our basic research. We need to support them. Right. So, it's not helping. And"
Testimony DR. THOMAS HWANG
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"All views here are my own only. The United States' leadership in biomedical innovation is built on strong and stable investments in research. Nearly every drug entering the U.S. market is linked to NIH-supported"
Testimony DR. JEFFERY TALBERT
“Building an AI-Ready America: How AI Is Creating Opportunities Across...
house Education and Workforce Committee · Jul 24, 2026
"Chairman Allen, Ranking Member McBath, and members of the committee, thank you for the opportunity to testify today on how artificial intelligence is creating opportunities across America's health care workforce. My name is Jeffrey Talbot, Professor and Chair of the Department of Artificial Intelligence and Health at Augusta University's Medical College of Georgia, and a Georgia Research Alliance eminent scholar with over 30 years of experience in biomedical informatics. The Medical College of..."
Testimony MR. THOMAS BOLLYKY
Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role ...
house Energy and Commerce Committee · Jul 15, 2026
"One of the foundations to the U.S. biomedical innovation system is robust funding for basic research. So, if we're trying to protect the U.S. system of biomedical innovation, We need to have an environment that attracts the best scientists,"
Testimony TRAHAN, LORI
Lowering Health Care Costs for All Americans: An Examination of the Pr...
house Energy and Commerce Committee · Feb 11, 2026
"Other countries, including China, are moving aggressively to attract clinical trials and accelerate biomedical innovation. At the same time, we're seeing real uncertainty and cuts in federal health research dollars here at home, which risks weakening the very ecosystem that has made the United States the global leader in biomedical breakthroughs. If America falls behind, we risk weaker supply chains, less domestic capacity, higher prices, and a reliance on other countries for our life-saving..."
Testimony GILLIBRAND, KIRSTEN E.
Hearings to examine truth in drug labeling.
senate Aging (Special) Committee · Jan 29, 2026
"I want to introduce Stephen Colville. Mr. Colville is an Assistant Research Director at the Duke-Margolis Institute for Health Policy, where he leads the Duke-Margolis Revamp Drug Supply Chain Consortium and policy work on other supply chain and biomedical innovation topics. Previously, Mr. Colville served in the White House Domestic Policy Council as Senior"